RACTHERA

RACTHERA is a biotechnology company focused on the development of regenerative medicine and cell therapies, primarily utilizing induced pluripotent stem (iPS) cell technology. Established in late 2024 as a joint venture between Sumitomo Chemical and Sumitomo Pharma, the company serves as the core entity for the Sumitomo Chemical Group's regenerative and cellular therapy business. RACTHERA's lead program, CT1-DAP001 (also known as DSP-1083), is an iPS cell-derived dopaminergic neural progenitor cell therapy for Parkinson's disease currently in late-stage clinical development and preparing for regulatory submission in Japan. The company's robust pipeline also includes allogeneic cell therapies for ophthalmic conditions such as retinal pigment epithelium tears and retinitis pigmentosa, as well as treatments for spinal cord injury. By leveraging advanced manufacturing expertise and strategic collaborations, including gene editing via CRISPR-Cas3 technology, RACTHERA aims to establish a global leadership position in the regenerative medicine market.